Regulatory Information
DUOPHARMA (SINGAPORE) PTE LTD
DUOPHARMA (SINGAPORE) PTE LTD
Therapeutic
Prescription Only
Formulation Information
CAPSULE
**RECOMMENDED DOSAGE**: **Adults:** Initially 500 mg followed by 250 mg 6 hourly as required. 1. **_Dysmenorrhoea._** 500 mg three times daily with meals from the onset of pain and continued for the usual duration of pain. 2. _**Menorrhagia.**_ 500 mg three times daily with meals from the onset of menses and continued according to the judgement of the physician. Therapy should not be continued for more than 7 days except on the advise of a physician. 3. _**Other indications.**_ Short term relief of mild to moderate pain such as dental pain and soft tissue pain – 500 mg three times daily. After assessing the risk/ benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used.
ORAL
Medical Information
**INDICATIONS:** For treatment of primary dysmenorrhoea and primary menorrhagia. Short term relief of mild to moderate pain such as dental pain and soft tissue pain.
**CONTRAINDICATIONS**: 01. In patients with ulceration or inflammation of gastrointestinal tract or known to be hypersensitive to mefenamic acid. 02. Patients in whom aspirin and / or other NSAIDs have induced symptoms of bronchospasm, allergic rhinitis or urticaria because the potential exists for cross sensitivity. 03. Patients with impaired renal function. 04. Patients previously experiencing diarrhoea on taking this drug. 05. Patients who have previously exhibited hypersensitivity to mefenamic acid. 06. Children under 14 years of age. 07. Preoperatively, in patients who have undergone coronary artery bypass graft (CABG) surgery and revascularization procedures. 08. Patients with severe uncontrolled heart failure. 09. Patients with cerebrovascular bleeding or other bleeding disorders. 10. Patients with severe liver impairment or active liver disease. 11. Patients with known hyperkalemia.
M01AG01
mefenamic acid
Manufacturer Information
DUOPHARMA (SINGAPORE) PTE. LTD.
DUOPHARMA (M) SDN BHD
Active Ingredients
Documents
Package Inserts
Pontacid Cap_PI.pdf
Approved: October 26, 2021